Dominik Ellenrieder is a Venture Partner at Endeavour Vision with over 20 years of experience in managing successful medical technology companies as an executive and board member in both Europe and in the USA.
Dominik held executive positions in R&D, product management, sales force and sales subsidiaries management and general management (as deputy CEO) at STRATEC Medical – a world leading company in orthopaedics and trauma. He was one of the core team who participated in the MBO in 1990, in the IPO on the SWX in 1996 and in the strategic sale to Synthes in 1999. He has held executive positions in marketing and product management at Straumann in the late Eighties, a company which is a world leader in fracture treatment, dental implants and metallurgy. Prior to that Mr. Ellenrieder held several positions in sales and finally served as Head of International Sales at Protek AG, a joint replacement company (Sulzer Medica, Zimmer).
Mr. Ellenrieder was a Co-Founder of Kuros Therapeutics, which was sold to Straumann and Co-Founder of Kuros Biosurgery – a biotech company focused on tissue and bone regeneration and a portfolio company of Genevest. He is the majority owner of Sentec AG (non-invasive monitoring) and co-owner of Medartis AG (small bone implants). He is currently serving as Board Member of Straumann, Medartis, Kuros Biosurgery and Sentec.
Dominik graduated with an economics degree from the University of Basel and holds an MBA from GSBA / Boston University.